Enhanced activity of central adrenergic neurons in two-kidney, one clip hypertension in Sprague-Dawley rats.
The present study was aimed at investigating whether two-kidney, one clip (2K1C) hypertension is associated with an enhanced central adrenergic activity. Rats were made 2K1C hypertensive, and the expression of Fos-like immunoreactivity (FLI) and phenylethanalamine N-methyltransferase (PNMT)-immunoreactivity was determined in the brain areas related to the cardiovascular regulation. In 2K1C hypertension, the basal Fos-immunoreactivity was significantly increased in rostral ventrolateral medulla (RVLM), paraventricular nucleus (PVN), and supraoptic nucleus (SON). PNMT-immunoreactivities were noted in RVLM, but not in PVN or SON. Intracerebroventricular administration of angiotensin II (AII) markedly increased Fos-immunoreactivities, the degree of which was greater in hypertension. Furthermore, AII increased the ratio of PNMT-positive/Fos-positive neurons in RVLM in hypertension. It is suggested that the responsiveness to AII of the central adrenergic system is enhanced in 2K1C hypertension.
Jung
Ji-Yeon
JY
Department of Physiology, College of Dentistry, Chonnam National University 300 YongBong-Dong, Buk-Gu, Gwang-Ju 500-757, South Korea.
Lee
Jong-Un
JU
Kim
Won-Jae
WJ
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D002452:Cell Count / Q000379:methods; D004195:Disease Models, Animal; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006978:Hypertension, Renovascular / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009599:Nitroprusside / Q000008:administration & dosage / Q000627:therapeutic use; D010625:Phenylethanolamine N-Methyltransferase / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011941:Receptors, Adrenergic / Q000378:metabolism*; D012078:Renal Artery Obstruction / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000959:Antihypertensive Agents; D016760:Proto-Oncogene Proteins c-fos; D011941:Receptors, Adrenergic; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D009599:Nitroprusside; D010625:Phenylethanolamine N-Methyltransferase